PMID- 25959522
OWN - NLM
STAT- MEDLINE
DCOM- 20160223
LR  - 20220317
IS  - 1873-3735 (Electronic)
IS  - 0165-6147 (Linking)
VI  - 36
IP  - 6
DP  - 2015 Jun
TI  - Towards universal therapeutics for memory disorders.
PG  - 384-94
LID - S0165-6147(15)00076-0 [pii]
LID - 10.1016/j.tips.2015.04.004 [doi]
AB  - Evidence is accumulating that many memory disorders, including those due to 
      neurodegenerative diseases, traumatic brain injury (TBI), vascular disease, or 
      abnormal brain development, share common features of memory-related pathology. 
      Structural and functional deficits of synapses are at the core of the underlying 
      pathophysiology, constituting a critical point of convergence in memory 
      disorders. Memory therapeutics that target synaptic loss and dysfunction - that 
      is, to slow, halt, or reverse progression of the disorders at the level of 
      synapses, via synaptogenic molecular cascades such as those of protein kinase C 
      (PKC) and brain-derived neurotrophic factor (BDNF) - possess universal 
      therapeutic value for many forms of memory disorder. They may be useful either as 
      standalone interventions for patients with memory disorders or as adjuncts to 
      drugs that target the underlying pathology.
CI  - Copyright (c) 2015 Elsevier Ltd. All rights reserved.
FAU - Sun, Miao-Kun
AU  - Sun MK
AD  - Blanchette Rockefeller Neurosciences Institute, 8 Medical Center Drive, 
      Morgantown, WV 26505, USA. Electronic address: mksun@brni-jhu.org.
FAU - Nelson, Thomas J
AU  - Nelson TJ
AD  - Blanchette Rockefeller Neurosciences Institute, 8 Medical Center Drive, 
      Morgantown, WV 26505, USA.
FAU - Alkon, Daniel L
AU  - Alkon DL
AD  - Blanchette Rockefeller Neurosciences Institute, 8 Medical Center Drive, 
      Morgantown, WV 26505, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20150507
PL  - England
TA  - Trends Pharmacol Sci
JT  - Trends in pharmacological sciences
JID - 7906158
RN  - 0 (Neuroprotective Agents)
SB  - IM
MH  - Animals
MH  - Humans
MH  - Memory Disorders/*drug therapy/metabolism/therapy
MH  - *Mesenchymal Stem Cell Transplantation
MH  - Neuroprotective Agents/*pharmacology/therapeutic use
MH  - Synapses/drug effects/*metabolism
MH  - *Synaptic Transmission
OTO - NOTNLM
OT  - brain-derived neurotrophic factor
OT  - learning and memory
OT  - memory disorders
OT  - post-traumatic stress disorder
OT  - protein kinase C
OT  - stem cell
EDAT- 2015/05/12 06:00
MHDA- 2016/02/26 06:00
CRDT- 2015/05/12 06:00
PHST- 2015/01/27 00:00 [received]
PHST- 2015/04/07 00:00 [revised]
PHST- 2015/04/08 00:00 [accepted]
PHST- 2015/05/12 06:00 [entrez]
PHST- 2015/05/12 06:00 [pubmed]
PHST- 2016/02/26 06:00 [medline]
AID - S0165-6147(15)00076-0 [pii]
AID - 10.1016/j.tips.2015.04.004 [doi]
PST - ppublish
SO  - Trends Pharmacol Sci. 2015 Jun;36(6):384-94. doi: 10.1016/j.tips.2015.04.004. 
      Epub 2015 May 7.